Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Asset Writedowns and Impairment: 2016-2025

Historic Asset Writedowns and Impairment for Niagen Bioscience (NAGE) over the last 10 years, with Sep 2025 value amounting to -$12,000.

  • Niagen Bioscience's Asset Writedowns and Impairment fell 200.00% to -$12,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.6 million, marking a year-over-year decrease of 3437.18%. This contributed to the annual value of -$1.3 million for FY2024, which is 234.85% down from last year.
  • Niagen Bioscience's Asset Writedowns and Impairment amounted to -$12,000 in Q3 2025, which was down 113.48% from $89,000 recorded in Q2 2025.
  • Niagen Bioscience's 5-year Asset Writedowns and Impairment high stood at $400,000 for Q2 2023, and its period low was -$1.4 million during Q4 2024.
  • For the 3-year period, Niagen Bioscience's Asset Writedowns and Impairment averaged around -$146,273, with its median value being $19,000 (2023).
  • Its Asset Writedowns and Impairment has fluctuated over the past 5 years, first surged by 8,100.00% in 2023, then slumped by 7,252.63% in 2024.
  • Over the past 5 years, Niagen Bioscience's Asset Writedowns and Impairment (Quarterly) stood at $198,000 in 2021, then crashed by 82.32% to $35,000 in 2022, then tumbled by 45.71% to $19,000 in 2023, then tumbled by 7,252.63% to -$1.4 million in 2024, then crashed by 200.00% to -$12,000 in 2025.
  • Its Asset Writedowns and Impairment was -$12,000 in Q3 2025, compared to $89,000 in Q2 2025 and -$1.3 million in Q1 2025.